LISCure and Celltrion to develop novel microbiome treatment for Parkinson’s disease

Korean startup LISCure Biosciences Inc. enters into a multi-year strategic R&D collaboration with Celltrion to identify novel microbiome therapy for Parkinson’s disease.

Parkinson’s disease is known to occur due to a low level of dopamine and abnormal aggregation of α-synuclein associated with gut dysbiosis, suggesting that microbiome-based therapies are potential therapeutic strategies for novel treatments of Parkinson’s disease. The global market of Parkinson’s disease treatment is anticipated to reach $ 11.5 billion in 2029 (CAGR=12.6%).

LISCure Biosciences Inc. is a clinical-stage biotech developing advanced microbiome technology with precision targets. Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea.

Under the agreement, Celltrion and LISCure intend to develop oral live biotherapeutic products (LBPs) for Parkinson’s disease. LISCure will lead the discovery of novel candidates, and Celltrion will be responsible for further clinical and regulatory development. LISCure will receive research funding and is eligible to receive additional payments as the project progresses.

LISCure advances brain-target bacterial exosome technology for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease based on its platform technology. Celltrion intends to leverage the collaboration to expand its business strategy of microbiome therapy and strengthen the neurodegenerative pipeline.

Also Read,